Market Research Report
Asia Pacific Stroke Management Market (2018 - 2024)
|Published by||KBV Research||Product code||763782|
|Published||Content info||98 Pages
Delivery time: 1-2 business days
|Asia Pacific Stroke Management Market (2018 - 2024)|
|Published: December 20, 2018||Content info: 98 Pages||
The Asia Pacific Stroke Management Market would witness market growth of 8.2% CAGR during the forecast period (2018 - 2024). Stroke is a medical emergency which occurs when the flow of the blood is restricted to the brain and as a result, brain cells start dying. Rise in incidence and prevalence of chronic diseases has been a major factor that is responsible for the growth of the stroke management market. Additionally, growing geriatric population, which is highly susceptible to strokes, growing diabetic population and usage of tobacco are other factors that are driving the growth of the market. However, the cost associated with the treatment and stringent government regulations pertaining to the approval of new and advances devices and drugs would limit the market growth. Asia-Pacific is the region with tremendous market potential, due to rising prevalence of strokes, which is due to growing incidence of chronic diseases and use of tobacco.
Based on Application, the market is segmented into Ischemic Stroke and Hemorrhagic Stroke. Based on Type, the market is segmented into Diagnostics and Therapeutics. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include ABBOTT Laboratories, B. Braun Melsungen Ag, Boston Scientific Corporation, Cardinal Health, Inc., Ge Healthcare, Glaxosmithkline Plc, Medtronic Plc., Siemens Aktiengesellschaft, Merck & Co., Inc., and Bristol-Myers Squibb Company.